ES8505717A1 - Un procedimiento para preparar una muteina sintetica de una proteina biologicamente activa - Google Patents

Un procedimiento para preparar una muteina sintetica de una proteina biologicamente activa

Info

Publication number
ES8505717A1
ES8505717A1 ES526541A ES526541A ES8505717A1 ES 8505717 A1 ES8505717 A1 ES 8505717A1 ES 526541 A ES526541 A ES 526541A ES 526541 A ES526541 A ES 526541A ES 8505717 A1 ES8505717 A1 ES 8505717A1
Authority
ES
Spain
Prior art keywords
mutein
procedure
active protein
synthetic
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES526541A
Other languages
English (en)
Spanish (es)
Other versions
ES526541A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27030446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8505717(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of ES526541A0 publication Critical patent/ES526541A0/es
Publication of ES8505717A1 publication Critical patent/ES8505717A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES526541A 1982-10-19 1983-10-18 Un procedimiento para preparar una muteina sintetica de una proteina biologicamente activa Expired ES8505717A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43515482A 1982-10-19 1982-10-19
US48616283A 1983-04-15 1983-04-15

Publications (2)

Publication Number Publication Date
ES526541A0 ES526541A0 (es) 1985-04-01
ES8505717A1 true ES8505717A1 (es) 1985-04-01

Family

ID=27030446

Family Applications (4)

Application Number Title Priority Date Filing Date
ES526541A Expired ES8505717A1 (es) 1982-10-19 1983-10-18 Un procedimiento para preparar una muteina sintetica de una proteina biologicamente activa
ES533053A Expired ES8506089A1 (es) 1982-10-19 1984-06-01 Un procedimiento para preparar una celula u organismo recombinante
ES533054A Granted ES533054A0 (es) 1982-10-19 1984-06-01 Un metodo para producir un gen que contiene una muteina sintetica de una proteina biologicamente activa
ES542829A Expired ES8608043A1 (es) 1982-10-19 1985-05-03 Un metodo para evitar la formacion de un enlace de disulfuro en una proteina.

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES533053A Expired ES8506089A1 (es) 1982-10-19 1984-06-01 Un procedimiento para preparar una celula u organismo recombinante
ES533054A Granted ES533054A0 (es) 1982-10-19 1984-06-01 Un metodo para producir un gen que contiene una muteina sintetica de una proteina biologicamente activa
ES542829A Expired ES8608043A1 (es) 1982-10-19 1985-05-03 Un metodo para evitar la formacion de un enlace de disulfuro en una proteina.

Country Status (23)

Country Link
EP (4) EP0109748B1 (OSRAM)
JP (2) JPS6128392A (OSRAM)
KR (1) KR910009900B1 (OSRAM)
AT (4) ATE61407T1 (OSRAM)
AU (1) AU563962B2 (OSRAM)
BE (1) BE898016A (OSRAM)
CA (1) CA1340861C (OSRAM)
CH (1) CH669395A5 (OSRAM)
DE (4) DE3380598D1 (OSRAM)
DK (2) DK168767B1 (OSRAM)
ES (4) ES8505717A1 (OSRAM)
FI (1) FI82266C (OSRAM)
FR (1) FR2534594B1 (OSRAM)
GB (1) GB2130219B (OSRAM)
GR (1) GR79408B (OSRAM)
IE (1) IE56026B1 (OSRAM)
IL (1) IL69970A (OSRAM)
LU (3) LU88761I2 (OSRAM)
NL (2) NL930119I2 (OSRAM)
NO (1) NO173740C (OSRAM)
NZ (1) NZ205922A (OSRAM)
PH (2) PH20343A (OSRAM)
PT (1) PT77512B (OSRAM)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
NZ208309A (en) * 1983-06-01 1988-04-29 Hoffmann La Roche Recombinant leukocyte, fibroblast, or immune interferons (rifn-#a#, b or #g#) with one cys residue replaced
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
DE3575072D1 (de) 1984-03-28 1990-02-08 Cetus Corp Pharmazeutische zusammensetzungen von mikrobenerzeugtem interleukin-2.
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
DE3574731D1 (de) * 1984-05-08 1990-01-18 Genetics Inst Ein menschlicher t-zellwachstumsfaktor.
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
NZ212207A (en) * 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin
US5683688A (en) * 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
CA1275954C (en) 1984-08-31 1990-11-06 Hing Cheug Wong 3'-expression enhancing fragments and method
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
WO1986002068A1 (fr) * 1984-09-26 1986-04-10 Takeda Chemical Industries, Ltd. Separation mutuelle de proteines
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition
US4857316A (en) * 1984-10-03 1989-08-15 Syntex (U.S.A.) Inc. Synergistic antiviral composition
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US6107465A (en) * 1984-12-21 2000-08-22 Otsuka Pharmaceutical Co., Ltd. IL-1β and derivatives thereof and drugs
DK172052B1 (da) * 1984-12-21 1997-09-29 Otsuka Pharma Co Ltd Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor
US5342614A (en) * 1984-12-21 1994-08-30 Otsuka Pharmaceutical Co., Ltd. Method of treating arthritus or inflammation with IL-1β or derivatives thereof
DE3500681A1 (de) * 1985-01-11 1986-07-17 Hoechst Ag, 6230 Frankfurt Verfahren zur isolierung und reinigung von lymphokinen
US4863849A (en) * 1985-07-18 1989-09-05 New York Medical College Automatable process for sequencing nucleotide
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) * 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
AU595864B2 (en) * 1986-03-14 1990-04-12 Otsuka Pharmaceutical Co., Ltd. Il-1 alpha derivatives and drugs
ATE72582T1 (de) * 1986-09-05 1992-02-15 Cetus Corp Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
US4987070A (en) * 1987-03-04 1991-01-22 Suntory Limited Use of a 97 amino acid leader sequence from the E. coli B-galactosidase gene for the production of hanp and hptc as fusion proteins
JP2879148B2 (ja) * 1987-07-07 1999-04-05 サイオス インコーポレイテッド 組換え繊維芽細胞成長因子
JP2602968B2 (ja) * 1987-11-04 1997-04-23 カリフォルニア バイオテクノロジー インコーポレイテッド 肺胞の界面活性タンパク類
EP0355460B1 (en) * 1988-08-24 2000-12-27 American Cyanamid Company Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization
US5079230A (en) * 1988-09-12 1992-01-07 Pitman-Moore, Inc. Stable bioactive somatotropins
CA2003886A1 (en) * 1988-12-16 1990-06-16 Anthony F. Purchio Cloning and expression of simian transforming growth factor-beta 1
AU620673B2 (en) * 1989-01-31 1992-02-20 Pharmacia & Upjohn Company Somatotropin analogs
DK0383599T3 (da) * 1989-02-17 1996-08-05 Merck & Co Inc Protein-anticancermiddel
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US6207798B1 (en) 1989-08-03 2001-03-27 Merck & Co., Inc. Modified PE40 toxin fusion proteins
US5173297A (en) * 1991-07-01 1992-12-22 Quest International Flavors & Food Ingredients Company Division Of Indopco, Inc. Bacteriocin from lactococcus lactis subspecies lactis
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
FR2671554A1 (fr) * 1991-01-11 1992-07-17 Clonatec Sa Peptides synthetiques derivant de l'antigene hbc du virus de l'hepatite b, leurs applications a la detection d'une infection par ce virus et a la vaccination contre l'hepatite b.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
US5814485A (en) * 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
DE19544167A1 (de) * 1995-11-17 1997-05-22 Schering Ag Verwendung von Interferon-ß zur Behandlung von Bronchialkarzinom bei Bestrahlungstherapie
AU6399996A (en) * 1996-06-19 1998-01-07 Chiron Corporation Bacterial production of interferon-beta using low levels of sodium and potassium ions
CN1100875C (zh) * 1998-03-06 2003-02-05 上海华晨生物技术研究所 新型重组人白细胞介素2的制备方法及其表达载体和工程菌
EP1276856A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
EP1935431A3 (en) 2000-05-15 2008-08-13 Health Research, Inc. Cancer treatments by using a combination of an antibody against her2 and interleukin-2
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US20030082138A1 (en) * 2001-09-18 2003-05-01 Chiron Corporation Methods for treating multiple sclerosis
KR100511749B1 (ko) * 2001-11-06 2005-09-02 선바이오(주) 변형된 인터페론-베타, 및 이의 화학적으로 변형된 배합체
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
RU2329274C2 (ru) 2002-09-11 2008-07-20 Фрезениус Каби Дойчланд Гмбх Способ получения производных гидроксиалкилкрахмала
ATE409048T1 (de) 2002-10-08 2008-10-15 Fresenius Kabi De Gmbh Pharmazeutisch aktive oligosaccharid-conjugate
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
ATE476448T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat- abstossung
BRPI0508470A (pt) * 2004-03-05 2007-07-31 Chiron Corp sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
EP1725589A1 (en) 2004-03-11 2006-11-29 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
WO2006015165A2 (en) * 2004-07-26 2006-02-09 Enzon Pharmaceuticals, Inc. Optimized interferon-beta gene
GB0523282D0 (en) 2005-11-15 2005-12-21 Isis Innovation Methods using pores
GB2453377A (en) 2007-10-05 2009-04-08 Isis Innovation Transmembrane protein pores and molecular adapters therefore.
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
ES2382058T3 (es) 2008-01-17 2012-06-04 Philogen S.P.A. Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
EP2307540B1 (en) 2008-07-07 2017-04-19 Oxford Nanopore Technologies Limited Enzyme-pore constructs
WO2010004273A1 (en) 2008-07-07 2010-01-14 Oxford Nanopore Technologies Limited Base-detecting pore
US9077937B2 (en) * 2008-11-06 2015-07-07 Alcatel Lucent Method and apparatus for fast channel change
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
CA2750879C (en) 2009-01-30 2018-05-22 Oxford Nanopore Technologies Limited Adaptors for nucleic acid constructs in transmembrane sequencing
CA2750874A1 (en) 2009-01-30 2010-08-05 Oxford Nanopore Technologies Limited Hybridization linkers
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
CA2826374C (en) 2011-02-11 2024-01-23 Oxford Nanopore Technologies Limited Mutant pores
MX384095B (es) 2011-03-11 2025-03-14 Hopitaux Paris Assist Publique Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad.
WO2013014451A1 (en) 2011-07-25 2013-01-31 Oxford Nanopore Technologies Limited Hairpin loop method for double strand polynucleotide sequencing using transmembrane pores
GB201119244D0 (en) 2011-11-08 2011-12-21 British American Tobacco Co Smoking article
EP3192804B1 (en) 2012-04-10 2019-08-28 Oxford Nanopore Technologies Limited Mutant lysenin pores
EP2875154B1 (en) 2012-07-19 2017-08-23 Oxford Nanopore Technologies Limited SSB method for characterising a nucleic acid
EP2964779B1 (en) 2013-03-08 2018-08-29 Oxford Nanopore Technologies Limited Use of spacer elements in a nucleic acid to control movement of a helicase
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
WO2014206899A1 (en) 2013-06-25 2014-12-31 Icm (Institut Du Cerveau Et De La Moelle Épinière) Boosting treg cells for treating alzheimer disease and related disorders
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
EP2918285A1 (en) 2014-03-11 2015-09-16 Université Pierre et Marie Curie (Paris 6) Interleukin-2 for treating food allergy
EP3137490B1 (en) 2014-05-02 2021-01-27 Oxford Nanopore Technologies Limited Mutant pores
AU2015310913B2 (en) 2014-09-01 2021-04-01 Oxford Nanopore Technologies Limited Mutant CsgG pores
US10266885B2 (en) 2014-10-07 2019-04-23 Oxford Nanopore Technologies Ltd. Mutant pores
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
US10801023B2 (en) * 2015-04-24 2020-10-13 University Of Florida Research Foundation, Inc. Methods of identifying biologically active random peptides in plants and libraries of plants expressing candidate biologically active random peptides
US10876109B2 (en) 2015-04-24 2020-12-29 University Of Florida Research Foundation, Inc. Methods of identifying biologically active random peptides in prokaryotic cells and libraries of prokaryotic cells expressing candidate biologically active random peptides
WO2016172445A2 (en) * 2015-04-24 2016-10-27 The University Of Florida Research Foundation, Inc. Methods of identifying biologically active random peptides in plants and libraries of plants expressing candidate biologically active random peptides
AU2016341241B9 (en) 2015-10-22 2021-11-18 Iltoo Pharma Pharmaceutical compositions of IL-2
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
AU2017281469B2 (en) 2016-06-22 2023-08-31 David Klatzmann Genetically modified T lymphocytes
KR20190129077A (ko) 2017-03-15 2019-11-19 팬디온 테라퓨틱스, 인코포레이티드 표적화된 면역관용
CA3064435A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3752178A1 (en) 2018-02-16 2020-12-23 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2020102556A1 (en) 2018-11-15 2020-05-22 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods of prognosis and classification for preeclampsia
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
WO2021116444A1 (en) 2019-12-12 2021-06-17 Iltoo Pharma Interleukin 2 chimeric constructs
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
AU2021230103A1 (en) 2020-03-06 2022-09-22 Assistance Publique - Hopitaux De Paris Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
EP4144761A4 (en) * 2020-04-29 2024-05-29 GenoPharm Inc. RECOMBINANT PROTEIN HAVING FUSED INTERFERON-BETA MUTEIN AND ANTIBODY, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
AU2021264372B2 (en) * 2020-04-29 2025-09-25 Abion Inc. Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant
EP4412631A1 (en) 2021-10-06 2024-08-14 Iltoo Pharma Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
JP7760716B2 (ja) * 2022-05-24 2025-10-27 ジェイ・エイチ・エム バイオファーマシューティカル（ハンチョウ）カンパニー リミテッド 組換えａ型ボツリヌス神経毒及びその調製方法
CN119731204A (zh) 2022-06-16 2025-03-28 赛福伦有限责任公司 抗pd-1抗体-衰减的il-2免疫偶联物及其用途
AU2022477937A1 (en) 2022-09-12 2025-04-10 Assistance Publique - Hôpitaux De Paris Interleukin-2 for use in treating autism spectrum disorder
EP4630035A1 (en) 2022-12-05 2025-10-15 Centre Hospitalier Universitaire de Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5359688A (en) * 1976-11-11 1978-05-29 Tanpakushitsu Kenkiyuu Shiyour Production of novel polypeptide
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ES8302096A1 (es) * 1980-04-03 1982-12-16 Biogen Nv Un metodo de producir un polipeptido que muestra una actividad immunologica obiologica de interferon de fibroblasto hu- mano.
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
NZ208309A (en) * 1983-06-01 1988-04-29 Hoffmann La Roche Recombinant leukocyte, fibroblast, or immune interferons (rifn-#a#, b or #g#) with one cys residue replaced
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins

Also Published As

Publication number Publication date
ES8506801A1 (es) 1985-08-01
PH20343A (en) 1986-12-04
NL960013I2 (nl) 1997-03-03
KR910009900B1 (ko) 1991-12-03
NZ205922A (en) 1987-11-27
CH669395A5 (OSRAM) 1989-03-15
ATE33503T1 (de) 1988-04-15
ATE46539T1 (de) 1989-10-15
ES8608043A1 (es) 1986-06-01
IL69970A (en) 1991-05-12
GB8327490D0 (en) 1983-11-16
FR2534594B1 (fr) 1987-06-19
ES533053A0 (es) 1985-06-16
PT77512A (en) 1983-11-01
GB2130219A (en) 1984-05-31
PT77512B (en) 1987-11-24
LU90413I2 (fr) 1999-09-07
NL930119I2 (nl) 1995-01-16
NL960013I1 (nl) 1996-10-01
JPH0568480B2 (OSRAM) 1993-09-29
AU2008683A (en) 1984-05-03
PH23702A (en) 1989-09-27
BE898016A (fr) 1984-02-15
NL930119I1 (nl) 1993-11-01
DK105892A (da) 1992-08-26
DK105892D0 (da) 1992-08-26
IE832380L (en) 1984-04-19
DK481383D0 (da) 1983-10-19
KR840006369A (ko) 1984-11-29
DK171681B1 (da) 1997-03-10
EP0109748B1 (en) 1988-04-13
NO173740C (no) 1994-01-26
IL69970A0 (en) 1984-01-31
EP0192811A1 (en) 1986-09-03
DE3382528D1 (de) 1992-04-16
FI833681A0 (fi) 1983-10-10
LU88761I2 (fr) 1996-11-05
ES533054A0 (es) 1985-08-01
DE3376271D1 (en) 1988-05-19
EP0192811B1 (en) 1991-03-06
LU88357I2 (fr) 1994-05-04
DK481383A (da) 1984-04-20
GR79408B (OSRAM) 1984-10-22
ES8506089A1 (es) 1985-06-16
DK168767B1 (da) 1994-06-06
GB2130219B (en) 1986-01-29
CA1340861C (en) 1999-12-28
ATE73493T1 (de) 1992-03-15
DE3380598D1 (en) 1989-10-26
NO833793L (no) 1984-04-24
ES542829A0 (es) 1986-06-01
EP0218825B1 (en) 1989-09-20
AU563962B2 (en) 1987-07-30
JPS6420096A (en) 1989-01-24
FI82266B (fi) 1990-10-31
ATE61407T1 (de) 1991-03-15
NO173740B (no) 1993-10-18
EP0234599B1 (en) 1992-03-11
FI833681L (fi) 1984-04-20
ES526541A0 (es) 1985-04-01
EP0218825A1 (en) 1987-04-22
EP0234599A1 (en) 1987-09-02
JPS6128392A (ja) 1986-02-08
FI82266C (fi) 1991-02-11
DE3382197D1 (de) 1991-04-11
EP0109748A1 (en) 1984-05-30
IE56026B1 (en) 1991-03-27
FR2534594A1 (fr) 1984-04-20

Similar Documents

Publication Publication Date Title
ES8505717A1 (es) Un procedimiento para preparar una muteina sintetica de una proteina biologicamente activa
AR245369A1 (es) Procedimiento para la fabricacion de una sal del acido hialuronico.
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
AU595290B2 (en) Process for producing human epidermal growth factor and analogs thereof
ES2056842T3 (es) Muteina de factor basico de crecimiento de fibroblastos, dna y su utilizacion.
ES8507610A1 (es) Produccion de activador de plasminogeno de tejido humano, utilizando vectores que codifican proteina de dihidrofolato- reductasa.
ES2125854T3 (es) Radiomarcado directo de anticuerpos y otras proteinas con tecnetio o renio.
EA200100749A1 (ru) Синтетические пептиды, обладающие поверхностной активностью, и их применение для приготовления синтетического сурфактанта
ES2075011T3 (es) Uso de sales del acido gamma-hidroxibutirico para preparar composiciones farmaceuticas para uso en el tratamiento del alcoholismo, y las composiciones obtenidas.
MX9302917A (es) Derivados de proteinas c humanas, procedimiento para su preparacion y formulacion famaceutica que los contiene.
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
NO843002L (no) Vandig loesning inneholdende en lipid-loeselig farmasoeytisk substans
ES8600783A1 (es) Procedimiento para la preparacion de la hormona polipeptidica factor de crecimiento de nervios de humano.
ES8700258A1 (es) Procedimiento para la obtencion de poli-hidro piridazo dia- cepinas triacepinas o diazocinas
ES8602112A1 (es) Procedimiento para preparar un polipeptido ciclico
ES2006476A6 (es) Un procedimiento para obtener interleukin-2 humana
ES2151517T3 (es) Efectos de filamentos de actina sobre la estructura y lisis de coagulos de fibrina.
Benezra et al. Enantiospecificity in allergic contact dermatitis A review and new results in Frullania‐sensitive patients
ES2077559T3 (es) Estabilizacion de proteinas terapeuticamente activas en preparados farmaceuticos.
ES2150902T3 (es) Procedimientos para potenciar la cicatrizacion de heridas y la reparacion de tejidos.
ES2013353A6 (es) Metodo de adn recombonante para producir proteinas fijadoras de oxigeno, particularmente hemoglobinas.
ES2089154T3 (es) Composicion cosmetica.
ES2124235T3 (es) Uso de tri(n-butil) fosfato a bajo ph en soluciones de proteinas biologicamente activas para mejorar la actividad viricida.
ES2126575T3 (es) Sacarosa-fosfato-sintasa (sps), su procedimiento de preparacion, su adnc, y utilizacion de adnc para modificar la expresion de sps en celulas vegetales.
ES2076933T3 (es) Nuevos sustratos peptidicos.

Legal Events

Date Code Title Description
PC1A Transfer granted
SPCD Supplementary protection certificate rejected

Free format text: INTERFERON BETA - 1B (BETAFERON) MOTIVO: NO CONTESTACION A SUSPENSO DE FECHA 20030901.

Spc suppl protection certif: C9900026

Filing date: 19990726

Effective date: 20040614